About AOBiome
AOBiome is a company based in Cambridge (United States) founded in 2012 by David Whitlock and Jamie Heywood. AOBiome has raised $33.71 million across 4 funding rounds from investors including ICarbonX. The company has 8 employees. AOBiome offers products and services including Cosmetic Mist and B244. AOBiome operates in a competitive market with competitors including Revance Therapeutics, Ardelyx, DermBiont, Hugel and Dermavant, among others.
- Headquarter Cambridge, United States
- Employees 8
- Founders David Whitlock, Jamie Heywood
- SectorsHealthcare
- Website aobiome.com
- Social LinkedIn X Facebook
- Legal Name Aobiome Llc
- Total Equity Funding$33.71M (USD)
in 4 rounds
- Latest Funding Round$30M (USD), Series C
Jan 2017
- Investors
- Employee Count8
Products & Services of AOBiome
AOBiome offers a comprehensive portfolio of products and services, including Cosmetic Mist and B244.
Mist that restores skin microbiome and reduces inflammation.
Bacteria-based treatment for inflammatory skin conditions.
Funding Insights of AOBiome
AOBiome has successfully raised a total of $33.71M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $30 million completed in January 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $33.71M
- Total Rounds 4
- Last Round Series C — $30M
- First Round $630,000
(Mar 2013)
- Investors Count 1
All 4 funding rounds of AOBiome with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2017 | $30M | Series C | – | – | |
| Sep 2015 | $2.5M | Series A | – | – | – |
| Oct 2014 | $576,513 | Series A | – | – | – |
| Mar 2013 | $630,000 | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in AOBiome
AOBiome has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include ICarbonX.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Bioinformatics platforms are provided for health management and drug development. | 2015 | icarbonx.com | Shenzhen, China |
Investor details for AOBiome
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of AOBiome
12 people are tracked at AOBiome (8 in leadership, 4 in board & advisors); the tracked headcount is 8.
| Name | Role | Group |
|---|---|---|
David Whitlock | Co-Founder | Leadership |
Jamie Heywood | Co-Founder | Leadership |
Todd Krueger | CEO | Leadership |
Ioannis Gryllos | VP, Manufacturing Operations & Quality | Leadership |
Hyun Kim | VP, Clinical Development | Leadership |
Jim Hoffman | Executive Vice President | Leadership |
Chris Johnson, MEM, MBA | Director Of Manufacturing | Leadership |
Connie Li | Chief of Staff & Director of Program Management | Leadership |
Annalisa Jenkins | Director | Board & advisors |
Douglas Rosefsky | Director | Board & advisors |
Jun Wang | Chairman | Board & advisors |
Klaus Dugi | Director | Board & advisors |
Complete people profiles for AOBiome
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of AOBiome
3 dated milestones of AOBiome across 5 years, from founding to its latest funding, stage changes and deals.
- Founded AOBiome is founded.
- Funding First funding round of $630K.
- Funding Latest funding round, Series C, of $30.0M.
Competitors of AOBiome
AOBiome operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Revance Therapeutics, Ardelyx, DermBiont, Hugel and Dermavant, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| revance.com | 2002 | Newark, United States | $154.56M | 597 | Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | |
| ardelyx.com | 2007 | Fremont, United States | $61.1M | 37 | Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | |
| dermbiont.com | 2015 | Melrose, United States | $78.91M | 14 | Microbial therapeutics for skin diseases are developed. | |
| hugel.co.kr | 2001 | Chuncheon-si, South Korea | – | – | Therapeutics in aesthetics are developed, including botulinum toxin products. | |
| dermavant.com | 2016 | Phoenix, United States | $160M | – | Small molecule therapeutics for inflammatory skin diseases are developed. | |
| inozyme.com | 2016 | Cambridge, United States | $116.4M | 59 | Developer of treatments for rare and debilitating metabolic diseases | |
| sol-gel.com | 1998 | United States | $9M | – | Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis. | |
| skinmedica.com | 1999 | Carlsbad, United States | $94.24M | – | Skin care products are developed and manufactured by SkinMedica. | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| vedantabio.com | 2010 | Cambridge, United States | $350.49M | 71 | Therapeutics for infectious and autoimmune diseases are developed. |
Detailed competitors of AOBiome
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of AOBiome
The website of AOBiome (aobiome.com) receives about 2.6K visits a month.
- Monthly visits2.6K
▲ 209% vs previous month
Websites whose visitors overlap most with AOBiome. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| medcitynews.com | 100% | 128.8K | #363,034 | View details | |
| medicaldaily.com | 67% | – | #269,414 | View details |
Latest news on Aobiome
Complete news archive for AOBiome
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to AOBiome
10 companies that operate in the same segment as AOBiome (Microbiome Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Biosolutions and enzymes are developed for biotechnology applications across industries. | 2000 | Bags Sword, Denmark | – | – | – | |
Pendulum is focused on developing advanced probiotic solutions. | 2012 | San Francisco, California, United States | USD 109.5 M | – | 55 | |
Gut microbiome insights, analytics, tests, and therapeutics are provided. | 2019 | Singapore, Singapore | USD 10.5 M | USD 1.37 M | – | |
Microbiome-based therapeutics for skin conditions like eczema are developed. | 2014 | Farmington, United States | USD 37.4 M | – | 12 | |
Engineered microbes are developed as programmable therapeutics for metabolic disorders. | 2013 | Cambridge, Massachusetts, United States | USD 34.4 M | USD 8 K | 1 | |
Therapeutics for infectious and autoimmune diseases are developed. | 2010 | Cambridge, Massachusetts, United States | USD 470.49 M | – | 71 | |
Biological drugs for skin and mucosa wound treatment are developed. | 2016 | Uppsala, Uppsala County, Sweden | USD 4.02 M | USD 1.12 M | – | |
Microbiome-based therapeutics for gut diseases are developed. | 2017 | Edinburgh, Scotland, United Kingdom | USD 72.96 M | – | 65 | |
The gut-brain axis is explored for therapeutic and nutritional innovations. | 2014 | New York, New York, United States | USD 479 M | – | 84 | |
Microbiome therapeutics are developed to address diverse diseases. | 2010 | Cambridge, Massachusetts, United States | USD 257.13 M | USD 789 K | 103 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about AOBiome
AOBiome was founded in 2012 and raised its 1st funding round 1 year after it was founded.
AOBiome is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Todd Krueger is the current CEO of AOBiome.
AOBiome is a funded company, having raised a total of $33.71M across 4 funding rounds to date. The company's 1st funding round was a Seed of $630K, raised on Mar 2013.
AOBiome has 8 employees.
AOBiome, formerly known as NitroCell Biosciences develops microbiome based therapies for inflammatory skin conditions. The company utilizes naturally occurring ammonia-oxidizing bacteria (AOB) to treat skin disorders. Its lead candidate is phase II clinical trials for adult acne. Other indications being explored include keratosis pilaris, eczema and rosacea. In addition, AOBiome has also launched a consumer product line under the brand name Mother Dirt. Mother Dirt is a range of skin and hair products that contain AOB.
AOBiome's top competitors include Revance Therapeutics, Ardelyx and Vedanta Biosciences.
AOBiome offers Cosmetic Mist and B244.
AOBiome has 1 investor. Key investors include ICarbonX.
AOBiome operates through Aobiome Llc.